BACKGROUND:Early treatment methods for colorectal cancer include endoscopy and surgical resection,but there are many postoperative complications.Chemotherapy is the most common treatment for late-stage colorectal cancer,but chemotherapy can cause gastrointestinal dysfunction,bone marrow suppression,liver and kidney function damage,and other adverse reactions.As a result,most patients are not proactive and do not cooperate with treatment.OBJECTIVE:To review the mechanism of action,latest treatment progress,and current problems of mesenchymal stem cells in the treatment of colorectal cancer,and provide a basis for future clinical application.METHODS:PubMed,CNKI,and WanFang databases were searched for relevant literature using the keywords of"mesenchymal stem cells,colorectal cancer,cancer stem cell,tumor microenvironment"in Chinese and English,respectively.Finally,119 articles were included for analysis.RESULTS AND CONCLUSION:(1)Mesenchymal stem cells have both promoting and inhibiting effects on colorectal cancer.(2)The tumor homing characteristics of mesenchymal stem cells enable them to migrate accurately to the tumor site and release drugs,which increases the safety and effectiveness of the treatment of colorectal cancer.(3)Exosomes derived from mesenchymal stem cells can serve as good carriers and shows a good application prospect in the targeted therapy of colorectal cancer.(4)Using viral vectors,non-viral vectors,or other transfection tools,drugs with mature anti-tumor effects can be loaded into mesenchymal stem cells for the treatment of colorectal cancer.(5)The combined use of mesenchymal stem cells and chemotherapy drugs can improve the efficacy of chemotherapy drugs and reduce the adverse reactions of chemotherapy drugs.(6)The mechanism by which mesenchymal stem cells promote the development of colorectal cancer is mainly related to the expression status of signal transduction and chemotactic factors in colorectal cancer cells and the transformation of mesenchymal stem cells into cancer-related fibroblasts.(7)Mesenchymal stem cells may have the characteristics of driving cancer stem cells,promoting tumor initiation and increasing tumor invasion.(8)There are still some unavoidable problems in the treatment of colorectal cancer with mesenchymal stem cells:lack of standardized treatment plans and efficacy evaluation,high treatment costs,preservation and transportation of mesenchymal stem cells,and the proportion of combined use of mesenchymal stem cells and chemotherapy drugs.

BACKGROUND:Currently,the treatment methods for colorectal cancer include surgical resection and chemotherapy.However,the subsequent quality of life of patients cannot be improved due to the multiple surgical complications and drug resistance in the later stage of chemotherapy.OBJECTIVE:To review the mechanism of action,latest progress and existing problems of exosomes derived from mesenchymal stem cells in the treatment of colorectal cancer.METHODS:PubMed,CNKI and WanFang databases were searched for relevant literature using the search terms of"mesenchymal stem cells exosomes,colorectal cancer,chemotherapy,treatment"in Chinese and English,respectively.Finally,96 articles were included for analysis.RESULTS AND CONCLUSION:(1)Mesenchymal stem cell-derived exosomes play different roles in the treatment of colorectal cancer mainly through the microRNAs and long-chain non-coding RNAs carried by themselves to mediate different signaling pathways.(2)Mesenchymal stem cell-derived exosomes are highly stable and biocompatible,which makes them excellent carriers of therapeutic drugs.(3)Mesenchymal stem cell-derived exosomes have different effects on resistance to different types of chemotherapeutic agents.

Objective:To investigate the risk factors influencing mortality in neonates undergoing continuous renal replacement therapy (CRRT).Methods:This retrospective study included 34 neonates with a corrected age of≤28 days who received CRRT at the Affiliated Children's Hospital of Xiangya School of Medicine, Central South University, from January 2019 to December 2023. The neonates were divided into a mortality group ( n=16) and a survival group ( n=18) based on whether they died during CRRT. Pre-CRRT blood biochemical indices, general condition, CRRT treatment modes, parameters, and related complications were analyzed using t-tests, Wilcoxon signed-rank tests, and Chi-square tests. Logistic stepwise regression analysis was used to screen for risk factors associated with CRRT mortality. Results:The mortality rate among the 34 neonates was 48.6% (16/34), with a median CRRT age of 17 days (range: 2-33 days). Eleven neonates (32.3%) were preterm, with the youngest gestational age being 27 weeks and the lowest weight before CRRT initiation being 1 700 g. The mortality group had lower urine output 6-12 hours before CRRT initiation and lower critical illness scores compared to the survival group [0.05 (0.02-1.00) ml/(kg·h) vs. 0.50 (0.20-1.05) ml/(kg·h), (64.50±7.10) scores vs. (77.67±3.65) scores, Z or t values were 10.97 and 3.91, respectively]. However, the vasoactive inotropic score (VIS), proportion of coma, and levels of blood potassium, alanine aminotransferase, aspartate aminotransferase, blood ammonia, blood lactic acid, and activated partial thromboplastin time (APTT) were higher in the mortality group compared to the survival group [ (86.88±15.80) scores vs. (55.56±24.31) scores, 11/16 vs. 1/18, (7.02±1.73) mmol/L vs. (5.88±1.53) mmol/L, 274.55(132.50-664.98) U/L vs. 31.10(19.03-110.70) U/L, 688.20 (449.73-3 618.13) U/L vs. 96.65 (44.15-439.00) U/L, 232.75 (70.33-1 310.85) μmol/L vs.77.70 (49.78-919.05) μmol/L, (11.17±3.36) U/L vs. (7.99±2.67) U/L, and (99.57±39.74) s vs. (60.97±31.25) s, with t, χ2, or Z values of－4.39, 14.81,－2.03,－2.72,－11.81,－3.89,－3.06, and－3.17, respectively] (all P<0.05). Logistic regression analysis revealed that pre-treatment VIS value ( OR=1.150, 95% CI: 1.035-1.278), and blood ammonia level ( OR=1.004, 95% CI: 1.002-1.009) were independent risk factors for mortality (both P<0.05). Conclusions:Neonatal CRRT mortality is associated with pre-treatment VIS scores and blood ammonia levels. Attention should be paid to a rapid decreases in urine output, the intensity of vasopressor support, and elevated levels of blood ammonia, blood lactic acid, transaminases, and APTT at the initiation of treatment.

SPF chickens were immunized with HN-mRNA vaccine by intramuscular injection.He-magglutination inhibition(HI)test,lymphocyte proliferation test,RT-qPCR and pathological sec-tions were used to evaluate the humoral and cellular immunity and protection against challenge in-duced by the candidate HN-mRNA vaccine.The results showed that 2.5,5.0,and 7.5 μg HN-mR-NA induced HI antibody antibodies in a dose-dependent manner.Among them,the Hi antibody in-duced by 7.5 μg HN-mRNA was slightly higher than that of the weak toxic vaccine(La Sota strain).In addition,in response to the stimulation of inactivated NDV virus,the proliferation and activation of lymphocytes in 2.5,5.0 and 7.5 μg HN-mRNA immunization groups and commercial vaccine group were observed.To further evaluate the antiviral protection provided by HN mRNA immunization,the 105 ELD50 NDV strong strain NA-1 was used to attack the 7.5 μg HN-mRNA immunised group and the commercial weakened vaccine(La Sota strain)and PBS groups using na-sal and ocular drops.The results showed that the survival rate of 7.5 μg HN-mRNA immunization group and commercial vaccine group was 100％,and these vaccines could protect tissues and or-gans from the damage caused by virus infection.At the same time,7.5 μg HN-mRNA and commer-cial vaccine could shorten the time of virus shedding in vitro and the viral load in vivo.This study provides a foundational framework for the clinical application of NDV HN mRNA candidate vac-cines and offers insights for the development of novel mRNA vaccines for poultry.

SPF chickens were immunized with HN-mRNA vaccine by intramuscular injection.He-magglutination inhibition(HI)test,lymphocyte proliferation test,RT-qPCR and pathological sec-tions were used to evaluate the humoral and cellular immunity and protection against challenge in-duced by the candidate HN-mRNA vaccine.The results showed that 2.5,5.0,and 7.5 μg HN-mR-NA induced HI antibody antibodies in a dose-dependent manner.Among them,the Hi antibody in-duced by 7.5 μg HN-mRNA was slightly higher than that of the weak toxic vaccine(La Sota strain).In addition,in response to the stimulation of inactivated NDV virus,the proliferation and activation of lymphocytes in 2.5,5.0 and 7.5 μg HN-mRNA immunization groups and commercial vaccine group were observed.To further evaluate the antiviral protection provided by HN mRNA immunization,the 105 ELD50 NDV strong strain NA-1 was used to attack the 7.5 μg HN-mRNA immunised group and the commercial weakened vaccine(La Sota strain)and PBS groups using na-sal and ocular drops.The results showed that the survival rate of 7.5 μg HN-mRNA immunization group and commercial vaccine group was 100％,and these vaccines could protect tissues and or-gans from the damage caused by virus infection.At the same time,7.5 μg HN-mRNA and commer-cial vaccine could shorten the time of virus shedding in vitro and the viral load in vivo.This study provides a foundational framework for the clinical application of NDV HN mRNA candidate vac-cines and offers insights for the development of novel mRNA vaccines for poultry.

Objective To compare the therapeutic value of endoscopic ligation surgery and surgical hemorrhoidectomy for internal hemorrhoids.Methods This study was a retrospective study,selected 340 patients with internal hemorrhoids admitted to the hospital from February 2023 to April 2025.According to the treatment method,they were divided into two groups:160 patients who underwent surgical hemorrhoidectomy as the control group and 180 patients who underwent endoscopic ligation surgery as the observation group.The surgical related indicators of the two groups were compared to evaluate postoperative anal pain,detect serum inflammatory factors,anal function,anorectal motility indicators,anal stenosis degree before and after surgery,and statistically analyze the incidence of complications.Results The observation group had a shorter surgical time,less intraoperative bleeding,and lower treatment costs compared to the control group,with statistically significant differences(P<0.05).On the 1st and 7th day after the surgery,the pain visual analogue scale(VAS)scores of the observation group were significant lower than those of the control group,with statisticlly significant differences(P<0.05).One month after the surgery,the levels of serum inflammatory factors in the observation group were lower than those of the control group,with statisticlly significant differences(P<0.05).One month after the surgery,the score of the anal function Kelly scale in the observation group was higher than that of the control group,with statisticlly significant difference(P<0.05).One month after the surgery,there were obvious differences in the levels of anorectal dynamic indicators between the two groups(P<0.05).The incidence of complications and the rate of anal stenosis in the observation group were relatively lower(P<0.05).Conclusion Both endoscopic ligation surgery and surgical hemorrhoidectomy can be used in the treatment of internal hemorrhoids.However,compared with the latter,the former is more effective in improving the patient's serum inflammatory factors,anal function,and postoperative pain.It can also shorten the patient's operation time,reduce the intraoperative blood loss,and relieve the patient's economic burden.

BACKGROUND:Early treatment methods for colorectal cancer include endoscopy and surgical resection,but there are many postoperative complications.Chemotherapy is the most common treatment for late-stage colorectal cancer,but chemotherapy can cause gastrointestinal dysfunction,bone marrow suppression,liver and kidney function damage,and other adverse reactions.As a result,most patients are not proactive and do not cooperate with treatment.OBJECTIVE:To review the mechanism of action,latest treatment progress,and current problems of mesenchymal stem cells in the treatment of colorectal cancer,and provide a basis for future clinical application.METHODS:PubMed,CNKI,and WanFang databases were searched for relevant literature using the keywords of"mesenchymal stem cells,colorectal cancer,cancer stem cell,tumor microenvironment"in Chinese and English,respectively.Finally,119 articles were included for analysis.RESULTS AND CONCLUSION:(1)Mesenchymal stem cells have both promoting and inhibiting effects on colorectal cancer.(2)The tumor homing characteristics of mesenchymal stem cells enable them to migrate accurately to the tumor site and release drugs,which increases the safety and effectiveness of the treatment of colorectal cancer.(3)Exosomes derived from mesenchymal stem cells can serve as good carriers and shows a good application prospect in the targeted therapy of colorectal cancer.(4)Using viral vectors,non-viral vectors,or other transfection tools,drugs with mature anti-tumor effects can be loaded into mesenchymal stem cells for the treatment of colorectal cancer.(5)The combined use of mesenchymal stem cells and chemotherapy drugs can improve the efficacy of chemotherapy drugs and reduce the adverse reactions of chemotherapy drugs.(6)The mechanism by which mesenchymal stem cells promote the development of colorectal cancer is mainly related to the expression status of signal transduction and chemotactic factors in colorectal cancer cells and the transformation of mesenchymal stem cells into cancer-related fibroblasts.(7)Mesenchymal stem cells may have the characteristics of driving cancer stem cells,promoting tumor initiation and increasing tumor invasion.(8)There are still some unavoidable problems in the treatment of colorectal cancer with mesenchymal stem cells:lack of standardized treatment plans and efficacy evaluation,high treatment costs,preservation and transportation of mesenchymal stem cells,and the proportion of combined use of mesenchymal stem cells and chemotherapy drugs.

Objective:To observe the application effect of dexmedetomidine in brain tumor resection surgery.Methods:60 patients who underwent brain tumor resection surgery in our hospital from September 2023 to September 2024 were selected,the patients were randomly divided into reference group(conventional anesthesia,n=30)and experimental group(reference group combined with dexmedetomidine,n=30)used random number table method.Neuron specific enolase(NSE),blood glucose,hemodynamic indicators[mean arterial pressure(MAP)and heart rate(HR)]between the two groups were compared,the recovery time,intraoperative opioid use,sedative level,extubation time,and occurrence of adverse reactions between the two groups were observed.Results:Compared with the time point of intubation(T1),MAP in the reference group decreased sequentially from the time point of beginning of surgery(T2)to the time point of skull drilling(T3)(P＜0.05).Compared with the end of surgery(T5),the MAP at time point of after returning to the intensive care unit(T6)in the reference group increased(P＜0.05).MAP in the experimental group decreased sequentially from the time point of before anesthesia induction(T0)to T2(P＜0.05).Compared with the time point of T5,MAP in the experimental group at time point of T6 increased(P＜0.05).MAP in the experimental group at time points of T1-T3 and T6 was lower than that in the reference group(P＜0.05).HR in the reference group at time points of T0～T2 first increased and then decreased(P＜0.05),Compared with HR at time point of T5,HR at time point of T6 in the reference group increased(P＜0.05).Compared with the time point of T1,HR in the experimental group decreased first and then increased from the time point of T2 to T3(P＜0.05).Compared with HR at time point of T5,HR at time point of T6 in the experimental group increased(P＜0.05).HR in the experimental group at time points of T1 to after tumor resection(T4)and T6 were lower than those in the reference group(P＜0.05).NSE levels increased in both groups at time points of T5,but the experimental group was lower than that in the control group(P＜0.05).Compared with the blood glucose at time point of T0 in the same group,the blood glucose at time point of T5 in the reference group increased,while the blood glucose at time point of T5 in the experimental group decreased,and the blood glucose at time point of T5 in the experimental group was lower than that in the reference group(P＜0.05).There was no significant difference in the recovery time,extubation time,and postoperative Ramsay score between the two groups(P＞0.05),but the dosage of remifentanil in the experimental group was lower than that in the reference group(P＜0.05).The overall incidence of adverse reactions in the experimental group was lower than that in the reference group(P＜0.05).Conclusion:The application of dexmedetomidine in patients undergoing brain tumor resection surgery can stabilize the hemodynamics of patients,inhibit the stress response,and significantly reduce the dosage of remifentanil and the risk of adverse reactions.It has good sedative effect and safety.

Objective:To observe the application effect of dexmedetomidine in brain tumor resection surgery.Methods:60 patients who underwent brain tumor resection surgery in our hospital from September 2023 to September 2024 were selected,the patients were randomly divided into reference group(conventional anesthesia,n=30)and experimental group(reference group combined with dexmedetomidine,n=30)used random number table method.Neuron specific enolase(NSE),blood glucose,hemodynamic indicators[mean arterial pressure(MAP)and heart rate(HR)]between the two groups were compared,the recovery time,intraoperative opioid use,sedative level,extubation time,and occurrence of adverse reactions between the two groups were observed.Results:Compared with the time point of intubation(T1),MAP in the reference group decreased sequentially from the time point of beginning of surgery(T2)to the time point of skull drilling(T3)(P＜0.05).Compared with the end of surgery(T5),the MAP at time point of after returning to the intensive care unit(T6)in the reference group increased(P＜0.05).MAP in the experimental group decreased sequentially from the time point of before anesthesia induction(T0)to T2(P＜0.05).Compared with the time point of T5,MAP in the experimental group at time point of T6 increased(P＜0.05).MAP in the experimental group at time points of T1-T3 and T6 was lower than that in the reference group(P＜0.05).HR in the reference group at time points of T0～T2 first increased and then decreased(P＜0.05),Compared with HR at time point of T5,HR at time point of T6 in the reference group increased(P＜0.05).Compared with the time point of T1,HR in the experimental group decreased first and then increased from the time point of T2 to T3(P＜0.05).Compared with HR at time point of T5,HR at time point of T6 in the experimental group increased(P＜0.05).HR in the experimental group at time points of T1 to after tumor resection(T4)and T6 were lower than those in the reference group(P＜0.05).NSE levels increased in both groups at time points of T5,but the experimental group was lower than that in the control group(P＜0.05).Compared with the blood glucose at time point of T0 in the same group,the blood glucose at time point of T5 in the reference group increased,while the blood glucose at time point of T5 in the experimental group decreased,and the blood glucose at time point of T5 in the experimental group was lower than that in the reference group(P＜0.05).There was no significant difference in the recovery time,extubation time,and postoperative Ramsay score between the two groups(P＞0.05),but the dosage of remifentanil in the experimental group was lower than that in the reference group(P＜0.05).The overall incidence of adverse reactions in the experimental group was lower than that in the reference group(P＜0.05).Conclusion:The application of dexmedetomidine in patients undergoing brain tumor resection surgery can stabilize the hemodynamics of patients,inhibit the stress response,and significantly reduce the dosage of remifentanil and the risk of adverse reactions.It has good sedative effect and safety.

Objective:To investigate the influencing factors of adult dental fluorosis in drinking water-borne endemic fluorosis areas of Inner Mongolia Autonomous Region.Methods:A case-control study was conducted in January 2024 to select adult fluorosis patients (case group) and healthy individuals (control group) from the drinking water-borne endemic fluorosis areas in Helinger County, Hohhot City, Inner Mongolia Autonomous Region as the survey subjects. Urine samples were collected to determine urinary fluoride concentration. A questionnaire survey was conducted. SPSS 25.0 software was used for χ 2 test and multivariate logistic regression analysis. Restricted cubic spline (RCS) was used to analyze the association between urinary fluoride concentration and the risk of dental fluorosis in adults. Results:A total of 161 individuals were included in the survey, including 100 in the case group and 61 in the control group. The results of univariate analysis showed that there were statistically significant differences in the distribution of gender, smoking, and urinary fluoride concentration between the case group and the control group (χ 2 = 7.54, 5.02, 9.69, P < 0.05). The results of multivariate logistic regression analysis indicated that gender ( OR = 0.36, 95% CI: 0.18 - 0.73, P = 0.005) and urinary fluoride concentration ( OR = 3.08, 95% CI: 1.46 - 6.67, P = 0.003) were the influencing factors of adult fluorosis. RCS analysis showed a significant linear dose-response relationship between the risk of dental fluorosis and urinary fluoride concentration ( Poverall trend = 0.001, Pnonlinear = 0.071). When the urinary fluoride concentration was greater than 1.57 mg/L, the risk of dental fluorosis increased with the increase of urinary fluoride concentration. Conclusion:Gender and urinary fluoride concentration are the risk factors of dental fluorosis in adults in drinking water-borne endemic fluorosis areas of Inner Mongolia Autonomous Region.